Skip to main content

Respiratory Medicine

News

Insulin resistance related to 31 diseases

Data analysis finds that insulin resistance is linked to 31 diseases, including sleeps disorders, bacterial infections and pancreatitis.

Sulthiame shows potential in OSA

Sulthiame 200 or 300 mg shows promise as a drug therapy for obstructive sleep apnea, reducing sleep disordered breathing and improving sleep quality.

Voice changes alert to COPD exacerbation

Early symptoms of a COPD exacerbation are accompanied by changes in the voice, meaning voice analysis may in the future help to recognize exacerbations early and allow timely interventions. 

Ultra-long-acting biologic reduces severe asthma exacerbations

Two doses of depemokimab over a year can significantly reduce the risk for severe asthma exacerbations compared with placebo.

Digital coach reduces errors in asthma medication inhalation

A digital coach in the form of an app helps asthma patients use their inhalation medication correctly. 

Depemokimab: a new option for severe asthma

Depemokimab is a new, long-acting biological drug for the treatment of severe eosinophilic asthma. The phase III studies SWIFT-I and SWIFT-II show that it can reduce the annual number of exacerbations. 

Bexotegrast shows potential for disease modification in IPF

Early trial results show that 12 weeks of treatment with the novel agent bexotegrast reduced type 1 collagen deposition in patients with idiopathic pulmonary fibrosis.

Benralizumab new treatment for asthma, COPD exacerbations

Benralizumab as a single injection at the time of an acute exacerbation of asthma or COPD is superior to standard prednisolone.

High corticosteroid peak doses adversely affect ICI efficacy

Higher peak doses of corticosteroids for immune-related adverse events are associated with worse outcomes across tumor types among patients receiving ICIs.

Speed of changes in ALS symptoms correlates with survival

Degree of change in disease burden between symptom onset and initial clinical evaluation could better predict prognosis in amyotrophic lateral sclerosis.

LAURA heralds practice change for locally advanced NSCLC

Osimertinib after chemoradiotherapy significantly improves the outcomes of patients with unresectable stage III EGFR-mutated NSCLC.

5-year CROWN update shows continued benefit of lorlatinib

Long-term data show continued benefit of first-line lorlatinib versus crizotinib in patients with advanced ALK-positive NSCLC.

Adagrasib improves PFS in previously treated KRAS-mutated NSCLC

Treatment with adagrasib leads to clinically meaningful improvement in progression-free survival compared with docetaxel in patients with previously treated KRAS G12C-mutated NSCLC.

Thermal ablation as effective as surgery for small colorectal liver metastases

Thermal ablation for small colorectal liver metastases is noninferior to surgery, and could reduce the number of complications and shorten hospital stays.

Subcutaneous amivantamab noninferior to intravenous administration

Subcutaneous amivantamab plus lazertinib is noninferior to intravenous amivantamab plus lazertinib as treatment for advanced EGFR-mutated NSCLC.

Tezepelumab shows potential in COPD

Phase 2a trial data point to the potential benefit of tezepelumab in patients with moderate to very severe chronic obstructive pulmonary disease.

Breathe easy — GLP-1 receptor agonist use not associated with post-op respiratory complications

The use of GLP-1 receptor agonists before emergency surgery does not put patients with type 2 diabetes at increased for postoperative respiratory complications.

Vaping increases risk of heart failure

Those who smoke e-cigarettes are more likely to develop heart failure, particularly HFpEF, than who have not vaped before.

Alectinib may cause androgen deficiency in men with NSCLC

An Italian study suggests the need to monitor for androgen deficiency in men with ALK-positive, advanced NSCLC receiving alectinib.

Female reproductive factors indicate risk for COPD

Multiple stages in women’s reproductive history are associated with an increased risk for chronic obstructive pulmonary disease.